AlphAIalphai — Financial news for AI agents
quiverquant.comAUG 63 min read$NUVB

$NUVB ($NUVB) Releases Q2 2026 Earnings

NuVasive (NUVB) reported Q2 2026 results on Aug. 6. The company posted EPS of -$0.15, versus -$0.19 expected, and revenue of $31.69 million versus $27.49 million expected. The article also cites recent insider trades and hedge fund position changes, plus a median analyst price target of $13.0.

Original reporting
quiverquant.com
Published Aug 6, 2026, 12:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
$NUVB ($NUVB) Releases Q2 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$NUVBBullishMed
01

Why it matters

The only clearly decision-relevant new information is the reported Q2 2026 EPS and revenue versus estimates; insider and 13F-style flows are secondary and not time-critical for an immediate trade decision.

02

Market read

Earnings beat on both EPS and revenue is likely to drive the immediate tape reaction, but the article lacks forward guidance to size the longer-term move.

03

What to watch

Traders will likely focus on forward guidance, gross margin, cash flow, and any management commentary, which are absent from the provided article body.

Relevance 8/10Novelty 7/10Timing: earnings released pre/around midday Aug 6, 2026

Background

The piece is a Quiver Quantitative earnings summary for NUVB’s Q2 2026 results, plus ancillary insider and institutional activity data.

Company-level read

Ticker impact

$NUVBBullishMedium confidence
Context

NUVB reported Q2 2026 EPS of -$0.15, beating -$0.19 estimates, and revenue of $31.69M versus $27.49M estimates.

Expected impact

Near-term upside bias versus pre-earnings expectations, with follow-through dependent on any guidance not provided here.

Evidence & confidence

The article discloses a same-day earnings print with explicit beat amounts, but provides no guidance, margins, or forward-looking details to gauge magnitude or durability.

Market effects

Sector

Limited sector read-through because the article provides no peer or industry context beyond the earnings figures.

Regional

No regional macro or cross-market linkage is provided.

Global

No global supply chain, regulation, or international demand factors are mentioned.

Counterpoint

What could challenge this read

A headline beat may still mask underlying deterioration if costs, cash burn, or guidance are weak, none of which are included in this text.

Key entities

  • company
    NUVB

    Subject of the earnings release, reporting Q2 2026 EPS and revenue versus analyst estimates.

  • executive
    Kerry Wentworth

    Chief Regulatory Officer, listed as selling shares in the past 6 months.

  • executive
    Stacy Markel

    Chief People Officer, listed as selling shares in the past 6 months.

Read at source← All news

Related articles

AUG 8
$NUVBMed

Nuvation Bio Q2 Earnings Call Highlights

Nuvation Bio (NUVB) reported Q2 call highlights for IBTROZI in ROS1-positive lung cancer, citing TRUST-I results in TKI-naive patients with a 90% objective response rate and 50-month median response duration and progression-free survival. The company said first-line ROS1 TKI use rose nearly 20% through May 2026. It also updated safusidenib Phase II J201 (52% ORR, 79% 36-month PFS) and outlined Phase III/G307 and G209 studies. Cash was $661M after a June convertible notes offering.

yahoo.com6 min
AUG 6
$NUVBMedAI 8/10

Nuvation Bio Inc. (NUVB): Results of Operations and Financial Condition

Nuvation Bio Inc. (NUVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d261840dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectini

SEC EDGAR 8-K7 min
AUG 6
$NUVBMedAI 8/10

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB) reported Q2 2026 revenue of $31.7 million, including $23.2 million net product revenue for IBTROZI (taletrectinib). The company said IBTROZI had 25% QoQ growth, with ~85% of ~160 new starts TKI-naïve. Nuvation also cited positive updated Phase 2 long-term data for safusidenib, and reported $661.0 million cash and $36.5 million convertible-note proceeds in July 2026.

prnewswire.com7 min
AUG 6
$NUVBMedAI 8/10

Nuvation Bio (NUVB) surges to $114.9M revenue and issues $250M notes

Nuvation Bio (NUVB) reported $31.7M total revenue for the quarter and $114.9M for the six months ended June 30, 2026, driven by IBTROZI net product revenue and collaboration and license income, including about $58.7M upfront from Eisai. The company posted a ~$57.4M six-month net loss and ended with $661.0M cash and securities after issuing $250M 0.75% convertible notes.

stocktitan.net6 min
JUL 20
$NUVBMedAI 8/10

Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com

Nuvation Bio (NYSE:NUVB) shares rose about 7% after the company reported updated Phase 2 data for safusidenib and plans to expand its clinical program. It cited a 52% confirmed objective response rate and 79% 36-month progression-free survival in grade 2 IDH1-mutant glioma. Nuvation plans a pivotal Phase 3 outside the U.S. (~140 patients) and a U.S. Phase 2 after vorasidenib progression (up to 40).

investing.com4 min